Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EuRSV
- Development stage
- Phase 1
- Lead developer
- EuBiologics
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EuRSV is a liposome nanoparticle-based recombinant protein subunit vaccine under development for the prevention of respiratory syncytial virus (RSV) infections. The vaccine combines the F protein antigen of the virus with an immune booster and is manufactured using proprietary technology from EuBiologics. It is being developed by EUPOP Life Sciences—a joint venture between Eubiologics and POP Biotechnologies—with clinical trials currently in Phase 1 to evaluate safety and tolerability in healthy adults. The primary indication is for prophylactic immunization against respiratory syncytial virus infections[1][4][7].
- Other names
- EuRSVRSV-1RSV1RSV 1RSV-1/2RSV-2RSV2RSV 2
02
Targets
BCR (Immunoglobulin G B Cell Receptor)TCR (T cell receptor)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on EuRSV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EuRSV.